IBDEI07Z ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3432,1,4,0)
 ;;=4^M62.838
 ;;^UTILITY(U,$J,358.3,3432,2)
 ;;=^5012682
 ;;^UTILITY(U,$J,358.3,3433,0)
 ;;=M62.50^^18^219^88
 ;;^UTILITY(U,$J,358.3,3433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3433,1,3,0)
 ;;=3^Muscle Wasting/Atrophy,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,3433,1,4,0)
 ;;=4^M62.50
 ;;^UTILITY(U,$J,358.3,3433,2)
 ;;=^5012655
 ;;^UTILITY(U,$J,358.3,3434,0)
 ;;=M62.81^^18^219^89
 ;;^UTILITY(U,$J,358.3,3434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3434,1,3,0)
 ;;=3^Muscle Weakness,Generalized
 ;;^UTILITY(U,$J,358.3,3434,1,4,0)
 ;;=4^M62.81
 ;;^UTILITY(U,$J,358.3,3434,2)
 ;;=^332922
 ;;^UTILITY(U,$J,358.3,3435,0)
 ;;=M61.9^^18^219^90
 ;;^UTILITY(U,$J,358.3,3435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3435,1,3,0)
 ;;=3^Muscle,Calcification/Ossification,Unspec
 ;;^UTILITY(U,$J,358.3,3435,1,4,0)
 ;;=4^M61.9
 ;;^UTILITY(U,$J,358.3,3435,2)
 ;;=^5012561
 ;;^UTILITY(U,$J,358.3,3436,0)
 ;;=M62.40^^18^219^91
 ;;^UTILITY(U,$J,358.3,3436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3436,1,3,0)
 ;;=3^Muscle,Contracture,Unspec Site
 ;;^UTILITY(U,$J,358.3,3436,1,4,0)
 ;;=4^M62.40
 ;;^UTILITY(U,$J,358.3,3436,2)
 ;;=^5012631
 ;;^UTILITY(U,$J,358.3,3437,0)
 ;;=M62.9^^18^219^84
 ;;^UTILITY(U,$J,358.3,3437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3437,1,3,0)
 ;;=3^Muscle Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,3437,1,4,0)
 ;;=4^M62.9
 ;;^UTILITY(U,$J,358.3,3437,2)
 ;;=^5012684
 ;;^UTILITY(U,$J,358.3,3438,0)
 ;;=M62.20^^18^219^92
 ;;^UTILITY(U,$J,358.3,3438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3438,1,3,0)
 ;;=3^Muscle,Nontraumatic Ischemic Infarction,Unspec Site
 ;;^UTILITY(U,$J,358.3,3438,1,4,0)
 ;;=4^M62.20
 ;;^UTILITY(U,$J,358.3,3438,2)
 ;;=^5012607
 ;;^UTILITY(U,$J,358.3,3439,0)
 ;;=M79.1^^18^219^93
 ;;^UTILITY(U,$J,358.3,3439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3439,1,3,0)
 ;;=3^Myalgia
 ;;^UTILITY(U,$J,358.3,3439,1,4,0)
 ;;=4^M79.1
 ;;^UTILITY(U,$J,358.3,3439,2)
 ;;=^5013321
 ;;^UTILITY(U,$J,358.3,3440,0)
 ;;=G72.1^^18^219^94
 ;;^UTILITY(U,$J,358.3,3440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3440,1,3,0)
 ;;=3^Myopathy,Alcoholic
 ;;^UTILITY(U,$J,358.3,3440,1,4,0)
 ;;=4^G72.1
 ;;^UTILITY(U,$J,358.3,3440,2)
 ;;=^5004096
 ;;^UTILITY(U,$J,358.3,3441,0)
 ;;=G72.81^^18^219^95
 ;;^UTILITY(U,$J,358.3,3441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3441,1,3,0)
 ;;=3^Myopathy,Critical Illness
 ;;^UTILITY(U,$J,358.3,3441,1,4,0)
 ;;=4^G72.81
 ;;^UTILITY(U,$J,358.3,3441,2)
 ;;=^328484
 ;;^UTILITY(U,$J,358.3,3442,0)
 ;;=G72.0^^18^219^96
 ;;^UTILITY(U,$J,358.3,3442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3442,1,3,0)
 ;;=3^Myopathy,Drug-Induced
 ;;^UTILITY(U,$J,358.3,3442,1,4,0)
 ;;=4^G72.0
 ;;^UTILITY(U,$J,358.3,3442,2)
 ;;=^5004095
 ;;^UTILITY(U,$J,358.3,3443,0)
 ;;=G72.41^^18^219^97
 ;;^UTILITY(U,$J,358.3,3443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3443,1,3,0)
 ;;=3^Myopathy,Inclusion Body Myositis
 ;;^UTILITY(U,$J,358.3,3443,1,4,0)
 ;;=4^G72.41
 ;;^UTILITY(U,$J,358.3,3443,2)
 ;;=^5004098
 ;;^UTILITY(U,$J,358.3,3444,0)
 ;;=G72.49^^18^219^98
 ;;^UTILITY(U,$J,358.3,3444,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3444,1,3,0)
 ;;=3^Myopathy,Inflammatory/Immune NEC
 ;;^UTILITY(U,$J,358.3,3444,1,4,0)
 ;;=4^G72.49
 ;;^UTILITY(U,$J,358.3,3444,2)
 ;;=^5004099
 ;;^UTILITY(U,$J,358.3,3445,0)
 ;;=G72.2^^18^219^99
 ;;^UTILITY(U,$J,358.3,3445,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3445,1,3,0)
 ;;=3^Myopathy,Other Toxic Agents
 ;;^UTILITY(U,$J,358.3,3445,1,4,0)
 ;;=4^G72.2
 ;;^UTILITY(U,$J,358.3,3445,2)
 ;;=^5004097
 ;;^UTILITY(U,$J,358.3,3446,0)
 ;;=G72.3^^18^219^100
